DCTH — Delcath Systems, Inc.

Summary of Delcath Systems Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: HEPZATO sales reached $19.3 million, up from $10 million in Q3 2024; CHEMOSAT sales were $1.3 million, slightly up from $1.2 million.
• Gross Margins: Improved to 87% from 85% year-over-year.
• Expenses: R&D expenses increased to $8.0 million from $3.9 million; SG&A expenses rose to $10.3 million from $7.0 million.
• Net Income: Reported at $0.8 million, down from $1.9 million in Q3 2024.
• Adjusted EBITDA: Positive at $5.3 million, up from $1.0 million in the prior year.
• Cash Position: Approximately $89 million in cash and investments, with positive operating cash flow of $4.8 million, down from $7.3 million in Q2.

2. Strategic Updates and Business Highlights

• Clinical Trials: Positive results from the CHOPIN trial were highlighted, showing significant improvements in progression-free survival and overall survival rates.
• Site Activation: The company activated 4 new treatment sites in the last two months, bringing the total to 25 REMS-certified sites. Plans to expand to 26-28 sites by the end of 2025 and 40 by the end of 2026.
• Sales Force Expansion: Increased from 4 to 6 regions in 2025, with plans to expand to 9 regions by Q2 2026 to enhance referral networks and site activations.
• Future Trials: Ongoing trials for metastatic colorectal cancer and breast cancer are expected to begin releasing data in 2027 and 2029, respectively.

3. Forward Guidance and Outlook

• 2025 Revenue Guidance: Adjusted to $83 million to $85 million, reflecting anticipated seasonality and competitive pressures.
• Gross Margin Forecast: Expected to remain between 85% and 87% for the remainder of 2025.
• Treatment Volume Growth: Projected to increase by nearly 150% in 2025 compared to 2024.

4. Bad News, Challenges, or Points of Concern

• 340B Pricing Impact: Participation in the NDRA program has led to a 13% reduction in average revenue per kit sold, with expectations of similar pricing in Q4.
• Seasonality and Competition: Noted seasonal slowdowns in patient starts and increased competition from other clinical trials, particularly from Thomas Jefferson University.
• Patient Enrollment: Concerns about the impact of competition on patient enrollment and treatment initiation, especially during holiday periods.

5. Notable Q&A Insights

• Q4 Expectations: Management anticipates modest seasonality in Q4 and has factored in ongoing competitive clinical trial activity.
• Site Additions: The pace of site additions is expected to accelerate in 2026, with a reasonable expectation of achieving the target of 40 active centers.
• Utilization Improvement: Strategies are in place to enhance patient utilization at lower-volume sites, including building referral networks and addressing physician prescribing behaviors.
• CHOPIN Trial Impact: Expected to influence utilization positively in 2026, with ongoing dissemination of trial results to alleviate physician concerns regarding HEPZATO's use in patients with extrahepatic disease.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, challenges, and insights from the Q&A session, providing a balanced view of Delcath Systems' current position and outlook.